VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.

[1]  E. Liu,et al.  Oncogenes and Tumor Suppressor Genes in Human Malignancies , 2012, Cancer Treatment and Research.

[2]  R. J. Cersosimo.  Tamoxifen for Prevention of Breast Cancer , 2003, The Annals of pharmacotherapy.

[3]  E. Petricoin,et al.  Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.

[4]  T. Moody,et al.  A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines , 2001, Cancer.

[5]  J. Green,et al.  2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. , 2001, Cancer research.

[6]  C. Paweletz,et al.  New approaches to proteomic analysis of breast cancer , 2001, Proteomics.

[7]  T. Moody,et al.  VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells , 2001, Breast Cancer Research and Treatment.

[8]  J. Reubi.  In Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications , 2000, Annals of the New York Academy of Sciences.

[9]  S. Hilsenbeck,et al.  9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J C Reubi,et al.  Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. , 2000, Cancer research.

[11]  Cheryl Jorcyk,et al.  The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.

[12]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[13]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[14]  T. Moody,et al.  PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells , 1999, Breast Cancer Research and Treatment.

[15]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[16]  T. Moody,et al.  VIP and Breast Cancer , 1998, Annals of the New York Academy of Sciences.

[17]  Robert F. Bonner,et al.  Laser Capture Microdissection: Molecular Analysis of Tissue , 1997, Science.

[18]  A. Constantinou,et al.  Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis , 1997, Breast Cancer Research and Treatment.

[19]  R. Clarke.  Animal models of breast cancer: experimental design and their use in nutrition and psychosocial research , 1997, Breast Cancer Research and Treatment.

[20]  G. Colditz,et al.  Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  T. Moody,et al.  Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. , 1996, Cancer Research.

[22]  J C Reubi,et al.  In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  J. Waschek,et al.  Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines. , 1995, Cancer letters.

[24]  S. Ethier,et al.  Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin‐like growth factor‐I in human mammary epithelial cells , 1995, Journal of cellular physiology.

[25]  S. Steinberg,et al.  Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. , 1994, Cancer research.

[26]  T. Harmar,et al.  Multiple receptors for PACAP and VIP. , 1994, Trends in pharmacological sciences.

[27]  Laurent Journot,et al.  Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.

[28]  S. Wank,et al.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Shigemoto,et al.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide , 1992, Neuron.

[30]  A. Arimura.  Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research , 1992, Regulatory Peptides.

[31]  T. Moody,et al.  An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. , 1991, The Journal of pharmacology and experimental therapeutics.

[32]  G. Bepler,et al.  Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels , 1990, Peptides.

[33]  P. de Cremoux,et al.  Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. , 1988, Cancer research.

[34]  P. Nettesheim.  Inhibition of carcinogenesis by retinoids. , 1980, Canadian Medical Association journal.

[35]  M. Sporn,et al.  Inhibition of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis by retinyl acetate. , 1976, Cancer research.

[36]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[37]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[38]  K. McKenzie,et al.  Molecular genetics of human breast cancer. , 1996, Progress in clinical and biological research.

[39]  J. Huff,et al.  Cellular and molecular mechanisms of hormonal carcinogenesis. Environmental influences. , 1996, Progress in clinical and biological research.

[40]  C. Benz,et al.  Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. , 1992, Cancer treatment and research.

[41]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .